Biogen downplays ‘premature’ talk of competition for SMA drug Spinraza
July 23, 2019 at 10:42 AM EDT
During an earnings call Tuesday morning, executives at Biogen Inc. brushed off investor concerns about competitors closing in on its key drugs.
